Jacobi Capital Management’s Trinity Biotech TRIB Stock Holding History

Jacobi Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-400	Closed	-$2K	–	1098
2019 Q3	$2K	Hold	400	–	–	﹤0.01%	959
2019 Q2	$3K	Hold	400	–	–	﹤0.01%	903
2019 Q1	$6K	Hold	400	–	–	﹤0.01%	772
2018 Q4	$5K	Hold	400	–	–	﹤0.01%	762
2018 Q3	$8K	Hold	400	–	–	﹤0.01%	733
2018 Q2	$10K	Hold	400	–	–	﹤0.01%	713
2018 Q1	$10K	Hold	400	–	–	﹤0.01%	691
2017 Q4	$10K	Hold	400	–	–	﹤0.01%	668
2017 Q3	$10K	Hold	400	–	–	﹤0.01%	644
2017 Q2	$11K	Hold	400	–	–	﹤0.01%	555
2017 Q1	$11K	Buy	+400	New	+$12.5K	0.01%	451
2016 Q3	–	Sell	-400	Closed	-$22K	–	749
2016 Q2	$22K	Buy	+400	New	+$22.5K	0.01%	335

Other funds holding TRIB

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ARM

Adirondack Research & Management Guilderland, New York $82.2M AUM 63.78% 1-Year Est. Return

Jacobi Capital Management's TRIB Position: Q4 2019 in Review

Jacobi Capital Management sold out of Trinity Biotech (TRIB) in Q4 2019, closing a stake of 400 shares — an estimated $2K sold.

Jacobi Capital Management first reported a position in TRIB in Q2 2016 and held it in 12 quarters. The position peaked at $22K in Q2 2016. 26 funds tracked by Wall St. Rank hold TRIB as of Q4 2019.

Jacobi Capital Management reported no remaining Trinity Biotech position as of Q4 2019 after selling out during the quarter.
Jacobi Capital Management sold 400 Trinity Biotech shares in Q4 2019, an estimated $2K.
Jacobi Capital Management first reported a position in Trinity Biotech in Q2 2016 and held it in 12 quarters.
Jacobi Capital Management's Trinity Biotech position peaked at $22K in Q2 2016.
26 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2019.

Based on Jacobi Capital Management's 13F filing for Q4 2019, filed 3 Feb 2020.